Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer

Ehteram, Hassan; Aslanbeigi, Fatemeh; Khorasani, Ebrahim Ghoochani; Tolouee, Mohammad; Kashani, Hamed Haddad

doi:10.1007/s40487-022-00205-4

Cited by 4 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As we moved from the proximal to the distal colon, there was a significant (p=0.025) increase in CD133 expression (Table 2). The incidence of high CD133 expression was maximum in the rectum (83.3%) and lowest in the right colon (25.0% [23,24]. However, none of these studies have explained the difference in CD133 expression at different sites of the large intestine.…”

Section: Discussionmentioning

confidence: 95%

“…Pop et al and Park et al also found increased CD133 expression in the distal part, but the difference was not statistically significant [ 21 , 22 ]. In contrast, Kostovski et al and Ehteram et al found higher CD133 expression in tumors occurring in the proximal part of the colon, but the difference was not significant [ 23 , 24 ]. However, none of these studies have explained the difference in CD133 expression at different sites of the large intestine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical Expression of the Stem Cell Marker CD133 in Colorectal Carcinoma

Suman¹,

Hota²,

Misra³

et al. 2023

Cureus

View full text Add to dashboard Cite

Background Colorectal carcinoma (CRC) is the second-leading cause of cancer-related death. Despite the combined (surgery, chemotherapy, radiotherapy, and immunotherapy) modalities of treatment, the prognosis remains poor, mostly because of recurrence and distant metastasis. Cancer stem cells (CSC) are thought to be responsible for the development and spread of tumors. Hence, targeted therapy against these cells hopes to reduce the chance of recurrence and metastasis and improve the prognosis. Many immune markers have been identified to detect CSC in CRC. Here, we tried to assess the immunohistochemical expression of the stem cell marker CD133 in colorectal carcinoma and its correlation with various pathological parameters. Methodology A total of 51 cases of CRC were analyzed. Immunohistochemistry for CD133 was done after standardization in our laboratory. Expression status was decided based on the total score obtained by multiplying the intensity score by the percentage score. CD133 expression was correlated with the age and gender of the patient, tumor location, histological grade, extent of invasion, lymphovascular invasion (LVI), perineural invasion (PNI), and nodal status. Results High CD133 expression was seen in 21 (41.17%) cases. There was no significant association between CD133 expression and the pathological parameters except the tumor site. CD133 expression was significantly higher as we moved from the proximal colon to the rectum. Conclusions CD133 expression was significantly higher in the distal part of the large intestine as compared to the proximal part. But there was no linear correlation between CD133 expression and histological grade, extent of invasion, or nodal status.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression of the Stem Cell Marker CD133 in Colorectal Carcinoma

Suman¹,

Hota²,

Misra³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Characteristic features of tumor stem-like cells include spherical formation, self-renewal to secondary neurospheres or subspheres, and expression of stem-like markers of their corresponding parental tumors . In our study, we have considered the expression of CD133, CD44, Nestin, VIM, and SOX2 as indicative of stemness markers, − IDH1 as a diagnostic marker of gliomas, GFAP as an astrocytic marker; and βIII-tubulin as a representative of neuronal differentiated cells . Our developed spheroids have shown enhanced self-renewal with expression of stemness gene markers of VIM, Nestin, CD44, GFAP, IDH1, and βIII-tubulin, which were confirmed by proteomic analysis.…”

Section: Discussionmentioning

confidence: 97%

Differential Proteome Profiling Analysis under Pesticide Stress by the Use of a Nano-UHPLC-MS/MS Untargeted Proteomic-Based Approach on a 3D-Developed Neurospheroid Model: Identification of Protein Interactions, Prognostic Biomarkers, and Potential Therapeutic Targets in Human IDH Mutant High-Grade Gliomas

Louati,

Maalej,

Kolsi

et al. 2023

J. Proteome Res.

View full text Add to dashboard Cite

High-grade gliomas represent the most common group of infiltrative primary brain tumors in adults associated with high invasiveness, agressivity, and resistance to therapy, which highlights the need to develop potent drugs with novel mechanisms of action. The aim of this study is to reveal changes in proteome profiles under stressful conditions to identify prognostic biomarkers and altered apoptogenic pathways involved in the anticancer action of human isocitrate dehydrogenase (IDH) mutant high-grade gliomas. Our protocol consists first of a 3D in vitro developing neurospheroid model and then treatment by a pesticide mixture at relevant concentrations. Furthermore, we adopted an untargeted proteomic-based approach with high-resolution mass spectrometry for a comparative analysis of the differentially expressed proteins between treated and nontreated spheroids. Our analysis revealed that the majority of altered proteins were key members in glioma pathogenesis, implicated in the cellular metabolism, biological regulation, binding, and catalytic and structural activity and linked to many cascading regulatory pathways. Our finding revealed that grade-IV astrocytomas promote the downstream of the mitogen-activated-protein-kinases/extracellular-signal-regulated kinase (MAPK1/ERK2) pathway involving massive calcium influx. The gonadotrophin-releasing-hormone signaling enhances MAKP activity and may serve as a negative feedback compensating regulator. Thus, our study can pave the way for effective new therapeutic and diagnostic strategies to improve the overall survival.

show abstract

“…CD133 (Prominin 1, PROM1) is a transmembrane protein whose mRNA and glycosylated forms are highly expressed in a variety of human cancer cells. CD133 is a cancer stem cell (CSC) marker and is associated with cancer progression and patient prognosis [ 114 , 115 ], including pancreatic cancer [ 116 ], colorectal cancer [ 117 ] and breast cancer [ 118 , 119 ]. Besides the application of CD133-targeted CAR T-cells in MLL leukemia [ 120 ], anti-CD133 CAR T-cells have been reported in a phase I trial including 14 patients with hepatocellular carcinoma (HCC), 7 patients with pancreatic carcinomas, and 2 patients with colorectal cancer [ 121 ].…”

Section: Car T-cell Therapy In Solid Tumorsmentioning

confidence: 99%

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Chen

Lü

2022

Cancers

View full text Add to dashboard Cite

Immunotherapy has been the fifth pillar of cancer treatment in the past decade. Chimeric antigen receptor (CAR) T-cell therapy is a newly designed adoptive immunotherapy that is able to target and further eliminate cancer cells by engaging with MHC-independent tumor-antigens. CAR T-cell therapy has exhibited conspicuous clinical efficacy in hematological malignancies, but more than half of patients will relapse. Of note, the efficacy of CAR T-cell therapy has been even more disappointing in solid tumors. These challenges mainly include (1) the failures of CAR T-cells to treat highly heterogeneous solid tumors due to the difficulty in identifying unique tumor antigen targets, (2) the expression of target antigens in non-cancer cells, (3) the inability of CAR T-cells to effectively infiltrate solid tumors, (4) the short lifespan and lack of persistence of CAR T-cells, and (5) cytokine release syndrome and neurotoxicity. In combination with these characteristics, the ideal CAR T-cell therapy for solid tumors should maintain adequate T-cell response over a long term while sparing healthy tissues. This article reviewed the status, clinical application, efficacy, safety, and challenges of CAR T-cell therapies, as well as the latest progress of CAR T-cell therapies for solid tumors. In addition, the potential strategies to improve the efficacy of CAR T-cells and prevent side effects in solid tumors were also explored.

show abstract

Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer

Cited by 4 publications

References 46 publications

Immunohistochemical Expression of the Stem Cell Marker CD133 in Colorectal Carcinoma

Immunohistochemical Expression of the Stem Cell Marker CD133 in Colorectal Carcinoma

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Contact Info

Product

Resources

About